Acorda Therapeutics has announced an additional late-stage trial of Fampridine-SR for multiple sclerosis. Researchers are working with the FDA to design a new Phase III study of the same or shorter duration as the recently completed trial. That study demonstrated that volunteers taking the drug experienced significantly improved walking speed [1]. Report [2]
Links:
[1] http://www.fiercebiotech.com/story/acorda-shares-soar-on-late-stage-ms-data/2006-09-25
[2] http://www.chron.com/disp/story.mpl/ap/fn/4388117.html